MCID: LGN006
MIFTS: 50

Legionnaire Disease

Categories: Genetic diseases, Immune diseases, Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Legionnaire Disease

MalaCards integrated aliases for Legionnaire Disease:

Name: Legionnaire Disease 56
Legionnaires' Disease 12 74 52 42 3 43 15 17 71
Legionnaires Disease 52 54 32
Legionella 12 15
Legionnaire Disease, Susceptibility to 56
Legionaire Disease, Susceptibility to 13
Infection by Legionella Pneumophilia 12
Legionnaire's Disease 12
Legionella Pneumonia 12
Legionellosis 52

Classifications:



External Ids:

Disease Ontology 12 DOID:10457
OMIM 56 608556
ICD9CM 34 482.84
MeSH 43 D007877
NCIt 49 C128339
SNOMED-CT 67 74881002
ICD10 32 A48.1
UMLS 71 C0023241

Summaries for Legionnaire Disease

NIH Rare Diseases : 52 Legionnaires' disease is a severe type of pneumonia caused by the bacteria Legionella . The species Legionella pneumophila causes most cases, but other species of Legionella can also cause the disease. It is named Legionnaires' disease because it was first discovered after a pneumonia outbreak among people who attended an American Legion Convention in Philadelphia, Pennsylvania in 1976. Most people exposed to Legionella do not become sick with Legionnaires' disease. People who do become sick usually develop symptoms within 2 to 10 days after exposure, but it may take longer. The first symptoms may include headache, chills, muscle pains, and a fever that can be 104?F (40?C) or higher. Additional symptoms usually develop 1 to 2 days after the first symptoms and may include coughing, shortness of breath, chest pain, diarrhea, nausea and vomiting, and confusion. While Legionnaires' disease mainly affects the lungs, it sometimes causes infections in other parts of the body, such as the heart or within body wounds. A person can become infected from Legionella when they inhale mist or water droplets that contain the bacteria. Sources of exposure may include showers, faucets, whirlpools, grocery store misters, and water droplets passing through ventilation systems in large buildings (such as hotels, office buildings, and hospitals). People who are more susceptible to developing Legionnaires' disease after an exposure include adults over age 50, current or former smokers, and people who have a weakened immune system or a chronic disease. Generally, neither the bacteria nor Legionnaires' disease is spread directly from person to person. While large exposures can result in outbreaks, the disease usually occurs in single, isolated cases. Legionnaires' disease may be suspected by symptoms. Pneumonia can be confirmed by a chest X-ray . Legionnaires' disease is diagnosed when one of the species of Legionella is found to be the cause of the pneumonia by testing a urine sample (urine culture ) or a sample of saliva and mucus that is coughed up (sputum culture ). Without treatment, the disease can be fatal. People with the disease who are otherwise healthy usually recover with antibiotics , although they may need to be cared for in a hospital. About 1 in 10 people with Legionnaires' disease will not survive due to complications such as respiratory failure, kidney failure, or septic shock. Of note, Legionella can also cause a milder illness called Pontiac fever , which causes flu-like symptoms, but does not cause pneumonia. Pontiac fever typically goes away without specific treatment.

MalaCards based summary : Legionnaire Disease, also known as legionnaires' disease, is related to legionellosis and pontiac fever, and has symptoms including fever, pruritus and snoring. An important gene associated with Legionnaire Disease is TLR5 (Toll Like Receptor 5), and among its related pathways/superpathways are Vesicle-mediated transport and Shigellosis. The drugs Levofloxacin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and kidney.

Disease Ontology : 12 A legionellosis that is characterized by severe form of infection producing pneumonia. Symptoms include fever, chills, and cough.

OMIM : 56 Legionnaire disease (LD) is a type of pneumonia caused by Legionella pneumophila, a flagellated gram-negative bacterium found primarily in warm water environments. The disease and the bacterium were discovered following an outbreak traced to a 1976 American Legion convention in Philadelphia. A number of risk factors for acquiring LD have been identified, including age, smoking, chronic lung disease, cancer, and immunosuppression (summary by Hawn et al., 2003). (608556)

MedlinePlus : 42 Legionnaires' disease is a type of pneumonia caused by bacteria. You usually get it by breathing in mist from water that contains the bacteria. The mist may come from hot tubs, showers, or air-conditioning units for large buildings. The bacteria don't spread from person to person. Symptoms of Legionnaires' disease include high fever, chills, a cough, and sometimes muscle aches and headaches. Other types of pneumonia have similar symptoms. You will probably need a chest x-ray to diagnose the pneumonia. Lab tests can detect the specific bacteria that cause Legionnaires' disease. Most people exposed to the bacteria do not become sick. You are more likely to get sick if you Are older than 50 Smoke Have a chronic lung disease Have a weak immune system Legionnaires' disease is serious and can be life-threatening. However, most people recover with antibiotic treatment. Centers for Disease Control and Prevention

CDC : 3 Legionnaires' (LEE-juh-nares) disease is a serious type of pneumonia (lung infection) caused by Legionella (LEE-juh-nell-a) bacteria. People can get sick when they breathe in mist or accidently swallow water into the lungs containing Legionella.

Wikipedia : 74 Legionnaires' disease, also known as legionellosis, is a form of atypical pneumonia caused by any type... more...

Related Diseases for Legionnaire Disease

Diseases related to Legionnaire Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 505)
# Related Disease Score Top Affiliating Genes
1 legionellosis 33.7 TLR5 SEC22B NLRC4 CD40LG CASP1 ARF1
2 pontiac fever 31.5 SEC22B HPSE ENSG00000276861 CD40LG ASPRV1
3 pneumonia 31.5 TLR5 PIK3C2A CRP CD40LG
4 bronchopneumonia 31.2 SERPINA3 CRP CD40LG
5 bacterial pneumonia 31.2 TLR5 CRP CD40LG
6 ornithosis 31.1 PIK3C2A CD40LG
7 chlamydia 30.9 CRP CD40LG CASP1
8 pericardial effusion 30.9 PIK3C2A CRP CD40LG
9 exanthem 30.9 PIK3C2A CRP CD40LG
10 tularemia 30.7 NLRC4 CD40LG CASP1
11 bronchiolitis 30.6 TLR5 CRP CD40LG
12 leptospirosis 30.6 PIK3C2A CRP CD40LG
13 streptococcus pneumonia 30.5 TLR5 CRP CD40LG
14 cat-scratch disease 30.5 CRP CD40LG
15 acalculous cholecystitis 30.5 CRP CD40LG
16 bacteriuria 30.5 TLR5 CRP CD40LG
17 toxoplasmosis 30.5 TLR5 CD40LG CASP1
18 aspiration pneumonia 30.5 PIK3C2A CRP CD40LG
19 gas gangrene 30.4 SERPINA3 PIK3C2A CRP
20 thrombocytopenia 30.3 TLR5 PIK3C2A HPSE CRP CD40LG
21 aortitis 30.3 CRP CD40LG
22 acute cystitis 30.2 TLR5 CRP CD40LG
23 typhoid fever 30.2 TLR5 CRP CD40LG CASP1
24 temporal arteritis 30.2 SERPINA3 CRP CD40LG
25 bacterial infectious disease 30.0 TLR5 SERPINA3 CRP CD40LG CASP1
26 cervical adenitis 29.9 CRP CD40LG
27 acute kidney failure 10.6
28 alkhurma hemorrhagic fever 10.6 PIK3C2A CD40LG
29 ocular toxoplasmosis 10.6 TLR5 CD40LG
30 kidney disease 10.6
31 rheumatic myocarditis 10.5 CRP ARF1
32 acute retinal necrosis syndrome 10.5 CD40LG ASPRV1
33 pyomyositis 10.5 PIK3C2A CRP
34 chronic orbital inflammation 10.5 CRP CD40LG
35 japanese spotted fever 10.5 CRP CD40LG
36 subdural empyema 10.5 CRP ASPRV1
37 neuroretinitis 10.5 CRP CD40LG
38 respiratory failure 10.5
39 intracranial sinus thrombosis 10.5 CRP CD40LG
40 splenic abscess 10.5 CRP CD40LG
41 optic papillitis 10.5 CRP CD40LG
42 late congenital syphilis 10.5 CRP CD40LG
43 tertiary syphilis 10.5 CRP CD40LG
44 arachnoiditis 10.5 CRP ASPRV1
45 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.5
46 granulomatous hepatitis 10.5 CRP CD40LG
47 gastrointestinal tuberculosis 10.5 CRP CD40LG
48 epiglottitis 10.5 CRP CD40LG
49 mononeuritis of upper limb and mononeuritis multiplex 10.5 CRP CD40LG
50 acute interstitial pneumonia 10.5 NLRC4 CRP

Graphical network of the top 20 diseases related to Legionnaire Disease:



Diseases related to Legionnaire Disease

Symptoms & Phenotypes for Legionnaire Disease

Clinical features from OMIM:

608556

UMLS symptoms related to Legionnaire Disease:


fever, pruritus, snoring, coughing

Drugs & Therapeutics for Legionnaire Disease

Drugs for Legionnaire Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
2
Ofloxacin Approved Phase 4 82419-36-1 4583
3
Azithromycin Approved Phase 4 83905-01-5 55185 447043
4
Clarithromycin Approved Phase 4 81103-11-9 84029
5
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7 Topoisomerase Inhibitors Phase 4
8 Fluoroquinolones Phase 4
9 Renal Agents Phase 4
10 Anti-Infective Agents, Urinary Phase 4
11 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
12 Antitubercular Agents Phase 4
13 Cytochrome P-450 CYP3A Inhibitors Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Erythromycin Ethylsuccinate Phase 4
16 Erythromycin Estolate Phase 4
17 Erythromycin stearate Phase 4
18 Immunoglobulins Phase 4
19 Antibodies Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Hormone Antagonists Phase 4
22 Antineoplastic Agents, Hormonal Phase 4
23 glucocorticoids Phase 4
24 Hormones Phase 4
25
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
26
Ceftaroline fosamil Approved, Investigational Phase 3 229016-73-3
27 beta-Lactams Phase 3
28 Lactams Phase 3
29 Cephalosporins Phase 3
30
Norgestimate Approved, Investigational Phase 1 35189-28-7 6540478
31
Estradiol Approved, Investigational, Vet_approved Phase 1 50-28-2 5757
32
Moxifloxacin Approved, Investigational Phase 1 151096-09-2, 354812-41-2 152946
33
Polyestradiol phosphate Approved Phase 1 28014-46-2
34
Ethinyl Estradiol Approved Phase 1 57-63-6 5991
35
Isoniazid Approved, Investigational Phase 1 54-85-3 3767
36
Nicotinamide Approved, Investigational Phase 1 98-92-0 936
37
Rifampicin Approved Phase 1 13292-46-1 5458213 5381226
38
Kanamycin Approved, Investigational, Vet_approved Phase 1 59-01-8, 8063-07-8 6032
39
Pyrazinamide Approved, Investigational Phase 1 98-96-4 1046
40
Streptomycin Approved, Vet_approved Phase 1 57-92-1 19649
41
Niacin Approved, Investigational, Nutraceutical Phase 1 59-67-6 938
42 Norgestimate, ethinyl estradiol drug combination Phase 1
43 Contraceptive Agents Phase 1
44 Estradiol 17 beta-cypionate Phase 1
45 Contraceptives, Oral, Combined Phase 1
46 Contraceptives, Oral Phase 1
47 Estradiol 3-benzoate Phase 1
48 Catalase Phase 1
49 Vitamin B3 Phase 1
50 Hypolipidemic Agents Phase 1

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Evaluation of a Clinical Pathway Based on Procalcitonin Levels for the Management of Community-acquired Pneumonia in Outpatients Unknown status NCT02600806 Phase 4 Azithromycin;Levofloxacin
2 Costs and Effects of Early Switch of Intravenous to Oral Antibiotics in Severe Community-Acquired Pneumonia: a Multicenter Randomized Trial Completed NCT00273676 Phase 4
3 Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
4 Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies Not yet recruiting NCT04036721 Phase 4 Prolonged glucocorticosteroid (prednisone) regimen;Short glucocorticosteroid (prednisone) regimen
5 A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia Completed NCT00509106 Phase 3 Ceftaroline fosamil for Injection;Ceftriaxone;Placebo
6 A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia Completed NCT00621504 Phase 3 Ceftaroline fosamil for Injection;IV Ceftriaxone;Placebo;Clarithromycin
7 A Randomized, Double-blind Study of the Effect of Beta-lactam on Treatment Response in Patients Hospitalized With Bacterial Pneumonia Completed NCT00111644 Phase 2 Ceftriaxone;beta-lactam;beta-lactam
8 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
9 Phase I Study for Positive IgM Antibody Detection in New Diagnostic Test Kit for for Acute Phase Infection Unknown status NCT01646411
10 The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia Unknown status NCT02203110
11 Epidemiology of Community Acquired Pneumonia in North Israel Unknown status NCT00390819
12 Prospective Study on Benefits Derived From Microbiological Tests in Community-Acquired Pneumonia Unknown status NCT00312741
13 The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly: PneumOldCT Unknown status NCT02467192
14 Microbiology and Clinical Outcome of Community Acquired Pneumonia and Health-Care-Associated Pneumonia in Taiwan: a Multi-Center Study Unknown status NCT00873522
15 Plasma Protein Biomarker Based Diagnostics of Outcome in Sepsis & CAP Unknown status NCT00258869
16 The Impact of Legionella Urine Antigen Testing (LUAT) on the Local Epidemiology and Diagnosis of Legionella Pneumonia - A Hospital Based Study in Malaysia Completed NCT03200275
17 Molecular Epidemiology of Legionellosis in Grenoble Region Completed NCT02884700
18 Zithromac Iv Special Investigation For Legionella Infection. Completed NCT01784770 Azithromycin IV
19 Prevalence of Legionella Infections, Bacterial Etiology in Pneumonia Among Patients Admitted to Hospital,- and Risk Factors/Characteristics for These Patients.(Translated From Norwegian) Completed NCT00467701
20 Pulmonary Complications of HIV Infection Study (PACS) Completed NCT00005273
21 A Multi-Center Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Unexplained Generalized Lymphadenopathy Completed NCT00002297 Inosine pranobex
22 Moxifloxacin Pharmacokinetic Profile and Efficacy Evaluation in the Empiric Treatment of Community-Acquired Pneumonia Completed NCT01983839
23 Etiology of Community Acquired Pneumonia Completed NCT00471757
24 Identification of Bacterial Species and Their Antibiotic-Resistant Spectrum in Sputum Specimen From the Patients With Pneumonia Via Nuclear Acid Detection Assay Completed NCT00567827
25 Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR Completed NCT00275691
26 Detection of Microorganisms and Antibiotic Resistance Genes in Lower Respiratory Tract (LRT) Samples Using the Curetis Unyvero LRT55 Application Completed NCT01922024
27 A Prospective Assessment of the Diagnostic Utility of Emerging Laboratory Assessments Used in Conjunction With FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates Completed NCT01328873
28 Infectious Etiology of Acute Exacerbations of COPD in Hong Kong Completed NCT00441389
29 Procalcitonin Antibiotic Consensus Trial (ProACT) Completed NCT02130986
30 Prevalence of Sleep Apnea-hypopnea Syndrome in Patients With Community Acquired Pneumonia, Prospective and Comparative Case-control Study Completed NCT01071421
31 Proposed Procalcitonin Re-Implementation Protocol for Johns Hopkins Bayview Medical Center (JHBMC): A Stewardship Project Completed NCT03109106
32 Randomized Controlled Trial of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit Completed NCT02056119
33 Nosocomial and Community Acquired Legionella Pneumophila Pneumonia, a Retrospective Case Series Recruiting NCT04106037
34 Bacterial and Human Biomarkers of Prognostic Value for Severe Legionnaire's Disease Recruiting NCT03064737
35 Legionella Pneumonia's Effect on Olfactory Function Recruiting NCT03321786
36 Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests (RDTs), Biomarkers, and Standard of Care Procedures (SoCs) for the Etiology Diagnoses of Pneumonia in Pediatric Patients to Improve Clinical Management in Indonesia. Recruiting NCT03366454
37 Impact of a Strategy Combining the Rapid Polymerase Chain Reaction Platform FilmArray® and the Intervention of an Antimicrobial Stewardship Team in Hospital-acquired Pneumonia in Non-mechanically Ventilated Patients: a Randomized Controlled Trial. Recruiting NCT04153682
38 Impact of Comprehensive Molecular Tests on Antimicrobial Stewardship in Community-acquired Pneumonia: an Open, Controlled and Randomized Clinical Trial Not yet recruiting NCT04158492
39 Evaluation of Legionella PCR Techniques for the Routine Diagnosis of Legionellosis Terminated NCT00452153

Search NIH Clinical Center for Legionnaire Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ERYTHROMYCIN PWDR

Cochrane evidence based reviews: legionnaires' disease

Genetic Tests for Legionnaire Disease

Anatomical Context for Legionnaire Disease

MalaCards organs/tissues related to Legionnaire Disease:

40
Lung, Testes, Kidney, Heart, T Cells, Monocytes, Bone

Publications for Legionnaire Disease

Articles related to Legionnaire Disease:

(show top 50) (show all 2898)
# Title Authors PMID Year
1
A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. 54 61 56 6
14623910 2003
2
Investigation of atmospheric conditions fostering the spreading of legionnaires' disease in outbreaks related to cooling towers. 61 42
31342243 2019
3
The cooling tower water microbiota: Seasonal dynamics and co-occurrence of bacterial and protist phylotypes. 61 42
31128471 2019
4
Impaired TLR5 functionality is associated with survival in melioidosis. 6
23447684 2013
5
A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. 6
16027372 2005
6
Potential false-positive urine Legionella enzyme immunoassay test results. 42
31119574 2019
7
Legionella community-acquired pneumonia (CAP) presenting with spontaneous bilateral pneumothoraces. 54 61
18482636 2008
8
Host susceptibility and clinical outcomes in toll-like receptor 5-deficient patients with typhoid fever in Vietnam. 54 61
15747241 2005
9
Residential water heater cleaning and occurrence of Legionella in Flint, MI. 61
31940510 2020
10
Serotyping and detection of pathogenecity loci of environmental isolates of Legionella pneumophila using MALDI-TOF MS. 61
31978736 2020
11
Legionella risk in evaporative cooling systems and underlying causes of associated breaches in health and safety compliance. 61
31978741 2020
12
Molecular detection of opportunistic premise plumbing pathogens in rural Louisiana's drinking water distribution system. 61
31740037 2020
13
Presence of Legionella spp. in cooling towers: the role of microbial diversity, Pseudomonas, and continuous chlorine application. 61
31726393 2020
14
Point-of-use filters for prevention of health care-acquired Legionnaires' disease: Field evaluation of a new filter product and literature review. 61
31668765 2020
15
The bacterial deubiquitinase Ceg23 regulates the association of Lys-63-linked polyubiquitin molecules on the Legionella phagosome. 61
31907282 2020
16
Inhaled Epoprostenol to Facilitate Safe Transport in Legionnaires' Disease. 61
31915089 2020
17
A pseudo-outbreak of Legionnaires' disease in an acute-care hospital. 61
31896386 2020
18
Complete Genome Sequence of a Legionella longbeachae Serogroup 2 Isolate Derived from a Patient with Legionnaires' Disease. 61
32001572 2020
19
The structure of the Legionella response regulator LqsR reveals amino acids critical for phosphorylation and dimerization. 61
31997467 2020
20
Development of a DGGE method to explore Legionella communities. 61
31922052 2020
21
Legionella pneumophila occurrence in drinking water supplied by private wells. 61
31904109 2020
22
Photocatalytic biocidal effect of copper doped TiO2 nanotube coated surfaces under laminar flow, illuminated with UVA light on Legionella pneumophila. 61
31940328 2020
23
Legionnaires' Disease: State of the Art Knowledge of Pathogenesis Mechanisms of Legionella. 61
31657966 2020
24
Legionnaires' Disease Cases at a Large Community Hospital-Common and Underdiagnosed. 61
31947755 2020
25
Transient parkinsonism associated with acute Legionnaires' disease. 61
31915186 2020
26
What is the risk of missing legionellosis relying on urinary antigen testing solely? A retrospective Belgian multicenter study. 61
31838606 2019
27
A cluster of Legionnaires' disease in Belgium linked to a cooling tower, August-September 2016: practical approach and challenges. 61
31858932 2019
28
[Legionella spp: An update]. 61
31703951 2019
29
Impact of temperature on Legionella pneumophila, its protozoan host cells, and the microbial diversity of the biofilm community of a pilot cooling tower. 61
31931228 2019
30
Water Quality as a Predictor of Legionella Positivity of Building Water Systems. 61
31847120 2019
31
Evaluation of the national surveillance of Legionnaires' disease in Norway, 2008-2017. 61
31795996 2019
32
Multiple Sources of the Outbreak of Legionnaires' Disease in Genesee County, Michigan, in 2014 and 2015. 61
31799878 2019
33
Legionella and legionellosis in touristic-recreational facilities: Influence of climate factors and geostatistical analysis in Southern Italy (2001-2017). 61
31541805 2019
34
Quorum sensing modulates the formation of virulent Legionella persisters within infected cells. 61
31740681 2019
35
Comparison of Whole-Genome Sequences of Legionella pneumophila in Tap Water and in Clinical Strains, Flint, Michigan, USA, 2016. 61
31625848 2019
36
TOLLIP deficiency is associated with increased resistance to Legionella pneumophila pneumonia. 61
31462698 2019
37
Viewing Legionella pneumophila Pathogenesis through an Immunological Lens. 61
31351897 2019
38
Antibiotic Resistance and Azithromycin Resistance Mechanism of Legionella pneumophila Serogroup 1 in China. 61
31405864 2019
39
Cost analysis for electron time-flow taps and point of use filters: a comparison of two methods for Legionnaires' disease prevention in hospital water networks. 61
31310790 2019
40
Legionnaires' Disease Mortality in Guinea Pigs Involves the p45 Mobile Genomic Element. 61
31268152 2019
41
Two sequential layers of antibody-mediated control of Legionella pneumophila infection. 61
31074841 2019
42
A real-time PCR for specific detection of the Legionella pneumophila serogroup 1 ST1 complex. 61
31525518 2019
43
Estimating the True Burden of Legionnaires' Disease. 61
31225857 2019
44
Evaluation and Treatment of Severe Rhabdomyolysis in a Patient with Legionnaires' Disease. 61
31723532 2019
45
Comparison of the Novel Immunocatch Legionella Test with Sofia Legionella FIA Assay and with BinaxNOW Legionella Card Assay for Detection of Legionella pneumophila (Serogroup 1) Antigen in Urine Samples. 61
31092595 2019
46
Inhibition of bacterial ubiquitin ligases by SidJ-calmodulin catalysed glutamylation. 61
31330532 2019
47
Overview and comparison of Legionella regulations worldwide. 61
30638676 2019
48
Population-Based Assessment of Clinical Risk Factors for Legionnaires' Disease. 61
31617567 2019
49
Comparison of Legiolert and a Conventional Culture Method for Detection of Legionella pneumophila from Cooling Towers in Québec. 61
30709427 2019
50
Potentiation of Cytokine-Mediated Restriction of Legionella Intracellular Replication by a Dot/Icm-Translocated Effector. 61
31036725 2019

Variations for Legionnaire Disease

ClinVar genetic disease variations for Legionnaire Disease:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TLR5 NM_003268.6(TLR5):c.1174C>T (p.Arg392Ter)SNV protective,risk factor 6658 rs5744168 1:223285200-223285200 1:223111858-223111858
2 TLR5 NM_003268.6(TLR5):c.1775A>G (p.Asn592Ser)SNV risk factor 6659 rs2072493 1:223284599-223284599 1:223111257-223111257

Expression for Legionnaire Disease

Search GEO for disease gene expression data for Legionnaire Disease.

Pathways for Legionnaire Disease

GO Terms for Legionnaire Disease

Cellular components related to Legionnaire Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome GO:0042470 9.5 SEC22B RAB5A RAB35
2 phagocytic vesicle membrane GO:0030670 9.33 SEC22B RAB5A OCRL
3 anchored component of synaptic vesicle membrane GO:0098993 9.26 RAB5A RAB35
4 clathrin-coated vesicle GO:0030136 9.13 RAB35 PIK3C2A OCRL
5 IPAF inflammasome complex GO:0072557 8.62 NLRC4 CASP1

Biological processes related to Legionnaire Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.55 TLR5 SERPINA3 NLRC4 CRP CD40LG
2 Rab protein signal transduction GO:0032482 9.43 RAB6A RAB5A RAB35
3 protein transport GO:0015031 9.43 SEC22B RAB6A RAB5A RAB35 ARF1 ANK2
4 phosphatidylinositol biosynthetic process GO:0006661 8.92 RAB5A PIK3C2A OCRL ARF1

Molecular functions related to Legionnaire Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 USH2A TLR5 SERPINA3 SEC22B RAB6A RAB5A
2 GDP binding GO:0019003 8.8 RAB5A RAB35 ARF1

Sources for Legionnaire Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....